Pharmacist Advanced Training Technician Training | Microcredentials | Opioids | Patient Safety | Point-of-Care Testing /Test & Treat Written 4 credit hours

The ongoing overdose crisis and rising rates of substance use–related infectious diseases require coordinated, community-based strategies that extend beyond traditional care models. This course discusses evidence-based approaches to overdose prevention and response, medications for opioid use disorder (MOUD), and infectious disease prevention, emphasizing the role of pharmacy professionals in supporting safety, treatment engagement, and care coordination across pharmacy and community settings. You will gain practical tools and implementation strategies to strengthen community partnerships, reduce stigma, and advance substance use health initiatives within your practice setting.


Overdose Prevention & Substance Use Disorder - Pharmacist

Claim Your Badge

You will receive an email from Credly (our credential partner), after you complete the course, inviting you to claim your digital badge for Overdose Prevention & Substance Use Disorder - Pharmacist. This will allow you to easily share your achievement with colleagues, managers, and your professional network on LinkedIn and other platforms. When you receive the email, please click the button and create an account on Credly.com so that you can “accept” the badge.

Need help? Find a step-by-step tutorial video at this link.

Learning Objectives

Upon successful completion of this application-based CPE course, pharmacists should be able to:
1. Define evidence-based overdose risk mitigation strategies and differentiate them from abstinence-based approaches.
2. Describe the role of CHWs in supporting overdose risk mitigation strategies both in the pharmacy and during patient home visits.
3. Demonstrate how stigma and language impact care delivery and patient engagement.
4. Recognize the signs of opioid overdose and outline steps for emergency response.
5. Describe naloxone formulations, administration, and post-overdose support strategies.
6. Perform CHW-specific roles related to ordering, stocking, demonstrating use, and education of naloxone.
7. Identify evidence-based overdose prevention tools (e.g., fentanyl test strips, safer drug use kits) and their role in patient safety.
8. Describe community engagement strategies for reaching high-risk populations.
9. Implement local overdose-prevention and risk-mitigation strategies.
10. Describe how MOUD works, including buprenorphine, naltrexone, and methadone.
11 Identify the clinical value of MOUD in reducing opioid-related harm and fatalities.
12. Demonstrate how MOUD reduces overdose risk and supports treatment retention.
13. Describe the role of CHWs in dispensing, counseling, and follow-up support for patients on MOUD.
14. Identify pharmacist-specific activities (e.g., administering naltrexone) and how CHWs can assist with them.
15. Respond to signs of underdosing or treatment disengagement and support patients accordingly.
16. Recognize the unique needs of special populations on MOUD.
17. Explain strategies for improving access to MOUD in rural vs. urban settings.
18. Develop strategies to overcome barriers and support patients in underserved communities.
19. Describe how hepatitis C is transmitted and why reinfection is a high risk for people who inject drugs.
20. Explain the framework of hepatitis C testing, treatment, and curative options.
21. Execute strategies to identify coverage and access pathways for hepatitis C treatment.
22. Summarize key tools for HIV and STI prevention, including PrEP, PEP, testing, and vaccination.
23. Describe how CHWs can support prevention efforts both in pharmacies and in homes.
24. Utilize region-specific HIV data to better understand local prevention priorities.
25. Explain how drug use and sexual health risks are interrelated in vulnerable populations.
26. Identify the CHW’s role in mitigating infection risk through education and care coordination.
27. Recommend appropriate testing and prevention resources within local communities. 

Faculty

Amy Tiemeier, PharmD, BCPS

Disclosures:

The content creators have no relevant financial relationships with ineligible companies to disclose.

Emily Palm, MBA, MSW

Disclosures:

The content creators have no relevant financial relationships with ineligible companies to disclose.

Francisco M. Franco, PharmD, MS, AAHIVP

Disclosures:

The content creators have no relevant financial relationships with ineligible companies to disclose.

Heather Lyons-Burney, Pharm.D.

Disclosures:

The content creators have no relevant financial relationships with ineligible companies to disclose.

Jordan Khail, PharmD, RPh

Disclosures:

The content creators have no relevant financial relationships with ineligible companies to disclose.

Phillip L. Marotta, PhD, MPH

Disclosures:

The content creators have no relevant financial relationships with ineligible companies to disclose.

Course Details